Table 1.
Patient characteristics
| Characteristics | |
|---|---|
|
Mean age, years (range) |
64 (range 46–79) |
| |
No. of patients (%) |
|
Gender | |
| Men |
14 (74%) |
| Women |
5 (26%) |
|
Diagnosis | |
| Multiple myeloma |
18 (95%) |
| Amyloidosis |
1 (5%) |
|
Peripheral Neuropathy (PN) | |
| Grade 2 |
13 (68%) |
| Grade 3 |
6 (32%) |
|
PN Treatment |
|
| Pregabalin |
11 (58%) |
| Gabapentin |
6 (32%) |
| None |
2 (10%) |
|
Pain Management* |
|
| Hydrocodone |
4 (21%) |
| Oxycodone |
3 (16%) |
| Morphine |
1 (5%) |
| Hydromorphone + bupivacaine (pump) |
1 (5%) |
|
Prior Therapy |
|
| Bortezomib |
16 (84%) |
| Thalidomide |
3 (16%) |
|
Dose of Prior Therapy |
|
| Bortezomib, mg (range) |
31.7 (10.5-64) |
| Thalidomide, g (range) |
84.7 (8.4-163) |
| No. Months Since Last Dose (range) | 9.8 (0.75-41.5) |
*Patients had to remain on same treatment regimen; however, minor adjustments in dosage were allowed.